Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.15252/emmm.202012697 http://scihub22266oqcxt.onion/10.15252/emmm.202012697 32473600!7300657!32473600     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       EMBO+Mol+Med 2020 ; 12 (8): e12697 Nephropedia Template TP {{tp|p=32473600|t=2020. Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients |pdf=|usr=}}{{32473600}} gab.com Text Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients JO: EMBO Mol Med http://www.kidney.de/pget.php?&tw=1&pmid=32473600 #FOAvip Baricitinib is an oral Janus kinase (JAK)1/JAK2 inhibitor approved for the treatment of rheumatoid arthritis (RA) that was independently predicted, using artificial intelligence (AI) algorithms, to be useful for COVID-19 infection via proposed anti-cytokine effects and as an inhibitor of host cell viral propagation. We evaluated the in vitro pharmacology of baricitinib across relevant leukocyte subpopulations coupled to its in vivo pharmacokinetics and showed it inhibited signaling of cytokines implicated in COVID-19 infection. We validated the AI-predicted biochemical inhibitory effects of baricitinib on human numb-associated kinase (hNAK) members measuring nanomolar affinities for AAK1, BIKE, and GAK. Inhibition of NAKs led to reduced viral infectivity with baricitinib using human primary liver spheroids. These effects occurred at exposure levels seen clinically. In a case series of patients with bilateral COVID-19 pneumonia, baricitinib treatment was associated with clinical and radiologic recovery, a rapid decline in SARS-CoV-2 viral load, inflammatory markers, and IL-6 levels. Collectively, these data support further evaluation of the anti-cytokine and anti-viral activity of baricitinib and support its assessment in randomized trials in hospitalized COVID-19 patients. Twit Text FOAVip Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients ????EMBO Mol Med http://www.kidney.de/pget.php?&tw=1&pmid=32473600 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32473600 #FOAvip English Wikipedia <ref>{{Cite pmid|32473600}}</ref> Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients #MMPMID32473600 Stebbing J; Krishnan V; de Bono S; Ottaviani S; Casalini G; Richardson PJ; Monteil V; Lauschke VM; Mirazimi A; Youhanna S; Tan YJ; Baldanti F; Sarasini A; Terres JAR; Nickoloff BJ; Higgs RE; Rocha G; Byers NL; Schlichting DE; Nirula A; Cardoso A; Corbellino M EMBO Mol Med 2020[Aug]; 12 (8): e12697 PMID32473600show ga Baricitinib is an oral Janus kinase (JAK)1/JAK2 inhibitor approved for the treatment of rheumatoid arthritis (RA) that was independently predicted, using artificial intelligence (AI) algorithms, to be useful for COVID-19 infection via proposed anti-cytokine effects and as an inhibitor of host cell viral propagation. We evaluated the in vitro pharmacology of baricitinib across relevant leukocyte subpopulations coupled to its in vivo pharmacokinetics and showed it inhibited signaling of cytokines implicated in COVID-19 infection. We validated the AI-predicted biochemical inhibitory effects of baricitinib on human numb-associated kinase (hNAK) members measuring nanomolar affinities for AAK1, BIKE, and GAK. Inhibition of NAKs led to reduced viral infectivity with baricitinib using human primary liver spheroids. These effects occurred at exposure levels seen clinically. In a case series of patients with bilateral COVID-19 pneumonia, baricitinib treatment was associated with clinical and radiologic recovery, a rapid decline in SARS-CoV-2 viral load, inflammatory markers, and IL-6 levels. Collectively, these data support further evaluation of the anti-cytokine and anti-viral activity of baricitinib and support its assessment in randomized trials in hospitalized COVID-19 patients. |*Artificial Intelligence[MESH] |*Betacoronavirus[MESH] |*Pandemics[MESH] |Adult[MESH] |Aged[MESH] |Antiviral Agents/pharmacokinetics/*pharmacology/therapeutic use[MESH] |Azetidines/pharmacokinetics/*pharmacology/therapeutic use[MESH] |COVID-19[MESH] |COVID-19 Drug Treatment[MESH] |Coronavirus Infections/*drug therapy[MESH] |Cytokines/antagonists & inhibitors[MESH] |Drug Evaluation, Preclinical[MESH] |Drug Repositioning[MESH] |Female[MESH] |Humans[MESH] |Intracellular Signaling Peptides and Proteins/antagonists & inhibitors[MESH] |Leukocytes/drug effects[MESH] |Liver[MESH] |Male[MESH] |Middle Aged[MESH] |Pneumonia, Viral/*drug therapy[MESH] |Protein Kinase Inhibitors/pharmacokinetics/pharmacology/*therapeutic use[MESH] |Protein Serine-Threonine Kinases/antagonists & inhibitors[MESH] |Purines[MESH] |Pyrazoles[MESH] |SARS-CoV-2[MESH] |Spheroids, Cellular/drug effects/virology[MESH]Mechanism of baricitinib supports artificial intelligence-predicted te(epmc).pdf DeepDyve Pubget Overpricing